Pharmacokinetics of paclitaxel and carboplatin in combination

C. M. Kearns, Chandra Belani, K. Erkmen, M. Zuhowski, D. Hiponia, D. Zacharski, C. Engstrom, R. Ramanathan, M. R. Trenn, J. Aisner, M. J. Egorin, Hainsworth, Alberts, Belani, Raghavan, Young, Ozols

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL · min, was administered as a 20-minute infusion immediately following paclitaxel. Neither the paclitaxel concentrations at the end of the infusion nor the terminal elimination of paclitaxel, as assessed by the duration of time that plasma paclitaxel concentrations were 0.05 μmol/L or greater, were different compared with historical data of paclitaxel as a single agent. Thus, we concluded that carboplatin bad no perceived effect on the pharmacokinetics of paclitaxel in this schedule. The observed areas under the concentration-time curves for carboplatin were consistently 10% to 15% less than the target values. Although this may indicate a possible interaction between paclitaxel and carboplatin, it also may have been a result of inadequate assessment of glomerular filtration rate, which was used to determine the carboplatin dose.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalSeminars in Oncology
Volume22
Issue number5 SUPPL. 12
StatePublished - 1995

Fingerprint

Carboplatin
Paclitaxel
Pharmacokinetics
Glomerular Filtration Rate
Intravenous Infusions
Non-Small Cell Lung Carcinoma
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kearns, C. M., Belani, C., Erkmen, K., Zuhowski, M., Hiponia, D., Zacharski, D., ... Ozols (1995). Pharmacokinetics of paclitaxel and carboplatin in combination. Seminars in Oncology, 22(5 SUPPL. 12), 1-7.
Kearns, C. M. ; Belani, Chandra ; Erkmen, K. ; Zuhowski, M. ; Hiponia, D. ; Zacharski, D. ; Engstrom, C. ; Ramanathan, R. ; Trenn, M. R. ; Aisner, J. ; Egorin, M. J. ; Hainsworth ; Alberts ; Belani ; Raghavan ; Young ; Ozols. / Pharmacokinetics of paclitaxel and carboplatin in combination. In: Seminars in Oncology. 1995 ; Vol. 22, No. 5 SUPPL. 12. pp. 1-7.
@article{09c4008a06f0456298d2d0b40e8d7fd5,
title = "Pharmacokinetics of paclitaxel and carboplatin in combination",
abstract = "We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL · min, was administered as a 20-minute infusion immediately following paclitaxel. Neither the paclitaxel concentrations at the end of the infusion nor the terminal elimination of paclitaxel, as assessed by the duration of time that plasma paclitaxel concentrations were 0.05 μmol/L or greater, were different compared with historical data of paclitaxel as a single agent. Thus, we concluded that carboplatin bad no perceived effect on the pharmacokinetics of paclitaxel in this schedule. The observed areas under the concentration-time curves for carboplatin were consistently 10{\%} to 15{\%} less than the target values. Although this may indicate a possible interaction between paclitaxel and carboplatin, it also may have been a result of inadequate assessment of glomerular filtration rate, which was used to determine the carboplatin dose.",
author = "Kearns, {C. M.} and Chandra Belani and K. Erkmen and M. Zuhowski and D. Hiponia and D. Zacharski and C. Engstrom and R. Ramanathan and Trenn, {M. R.} and J. Aisner and Egorin, {M. J.} and Hainsworth and Alberts and Belani and Raghavan and Young and Ozols",
year = "1995",
language = "English (US)",
volume = "22",
pages = "1--7",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 12",

}

Kearns, CM, Belani, C, Erkmen, K, Zuhowski, M, Hiponia, D, Zacharski, D, Engstrom, C, Ramanathan, R, Trenn, MR, Aisner, J, Egorin, MJ, Hainsworth, Alberts, Belani, Raghavan, Young & Ozols 1995, 'Pharmacokinetics of paclitaxel and carboplatin in combination', Seminars in Oncology, vol. 22, no. 5 SUPPL. 12, pp. 1-7.

Pharmacokinetics of paclitaxel and carboplatin in combination. / Kearns, C. M.; Belani, Chandra; Erkmen, K.; Zuhowski, M.; Hiponia, D.; Zacharski, D.; Engstrom, C.; Ramanathan, R.; Trenn, M. R.; Aisner, J.; Egorin, M. J.; Hainsworth; Alberts; Belani; Raghavan; Young; Ozols.

In: Seminars in Oncology, Vol. 22, No. 5 SUPPL. 12, 1995, p. 1-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of paclitaxel and carboplatin in combination

AU - Kearns, C. M.

AU - Belani, Chandra

AU - Erkmen, K.

AU - Zuhowski, M.

AU - Hiponia, D.

AU - Zacharski, D.

AU - Engstrom, C.

AU - Ramanathan, R.

AU - Trenn, M. R.

AU - Aisner, J.

AU - Egorin, M. J.

AU - Hainsworth,

AU - Alberts,

AU - Belani,

AU - Raghavan,

AU - Young,

AU - Ozols,

PY - 1995

Y1 - 1995

N2 - We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL · min, was administered as a 20-minute infusion immediately following paclitaxel. Neither the paclitaxel concentrations at the end of the infusion nor the terminal elimination of paclitaxel, as assessed by the duration of time that plasma paclitaxel concentrations were 0.05 μmol/L or greater, were different compared with historical data of paclitaxel as a single agent. Thus, we concluded that carboplatin bad no perceived effect on the pharmacokinetics of paclitaxel in this schedule. The observed areas under the concentration-time curves for carboplatin were consistently 10% to 15% less than the target values. Although this may indicate a possible interaction between paclitaxel and carboplatin, it also may have been a result of inadequate assessment of glomerular filtration rate, which was used to determine the carboplatin dose.

AB - We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a target area under the concentration-time curve of 5, 7, 9, or 11 mg/mL · min, was administered as a 20-minute infusion immediately following paclitaxel. Neither the paclitaxel concentrations at the end of the infusion nor the terminal elimination of paclitaxel, as assessed by the duration of time that plasma paclitaxel concentrations were 0.05 μmol/L or greater, were different compared with historical data of paclitaxel as a single agent. Thus, we concluded that carboplatin bad no perceived effect on the pharmacokinetics of paclitaxel in this schedule. The observed areas under the concentration-time curves for carboplatin were consistently 10% to 15% less than the target values. Although this may indicate a possible interaction between paclitaxel and carboplatin, it also may have been a result of inadequate assessment of glomerular filtration rate, which was used to determine the carboplatin dose.

UR - http://www.scopus.com/inward/record.url?scp=0028862356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028862356&partnerID=8YFLogxK

M3 - Article

C2 - 7481850

AN - SCOPUS:0028862356

VL - 22

SP - 1

EP - 7

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 12

ER -

Kearns CM, Belani C, Erkmen K, Zuhowski M, Hiponia D, Zacharski D et al. Pharmacokinetics of paclitaxel and carboplatin in combination. Seminars in Oncology. 1995;22(5 SUPPL. 12):1-7.